Similarly, bicistronic CD19/CD22 CAR-T cells in pediatric leukemia showed no severe CRS or neurotoxicity, suggesting that dual targeting can maintain anti-tumor efficacy while curbing inflammatory overload [54]. The gene discussed is CD19; the disease is congenital rubella syndrome.